Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis
Tobey J MacDonald1, Ian F Pollack, Hideho Okada
1Center for Cancer and Immunology Research, Children's Research Institute, Department of Hematology-Oncology, Children's National Medical Center, Washington, DC, USA.
Methods in Molecular Biology (Clifton, N.J.)
|July 20, 2007
Summary
Researchers identified nine genes consistently altered in high-grade astrocytomas, regardless of patient age. Downregulation of APOD, a gene inhibiting cell proliferation, suggests it may be a novel therapeutic target for malignant astrocytoma.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genomics
Background:
- Astrocytomas are classified into four World Health Organization (WHO) grades (I-IV), with prognosis worsening with higher grades.
- Molecular alterations drive astrocytoma progression, but age-specific differences complicate understanding.
- High-grade astrocytomas (WHO grades III-IV) in both children and adults have a poor prognosis.
Purpose of the Study:
- To identify gene expression changes consistently associated with high-grade astrocytomas, independent of patient age.
- To investigate potential universal molecular targets for therapeutic intervention in malignant astrocytomas.
Main Methods:
- Reanalysis of microarray datasets from pediatric and adult astrocytoma patients.
- Application of four novel statistical tests to identify differentially expressed genes.
- Validation of gene expression findings using an independent astrocytoma dataset.
Main Results:
- Nine genes were consistently dysregulated in high-grade astrocytomas across all applied tests.
- Four ribosomal protein genes (RPS2, RPS8, RPS18, RPL37A) were upregulated.
- Five genes (APOD, SORL1, SPOCK2, PRSS11, ID3) were downregulated, with APOD showing the most significant differential expression.
Conclusions:
- Specific gene expression profiles are associated with high-grade astrocytomas irrespective of patient age.
- The downregulation of APOD, which inhibits proliferation, suggests its critical role in malignant astrocytoma development.
- APOD represents a potential novel therapeutic target for astrocytoma treatment.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...